Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Transplant-Related Disorder Clinical Trial

Official title:

A Prospective, Single-arm Clinical Trial of Prevention of Severe Acute Graft-versus-host Disease After Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Using a daGOAT Model

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05600855
• Other study ID #: daGOAT-adult-001
• Status: Recruiting
• Phase: Phase 2
• Start date: January 15, 2023
• Est. completion date: December 1, 2025

Study information

• Verified date: March 2023
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Xueou Liu, PhD
• Phone: 022-23909051
• Email: liuxueou[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of adult patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model.

Description:

This study aims to prospectively evaluate the use of the daGOAT model in real-world clinical settings at the Institute of Hematology, Chinese Academy of Medical Sciences (IHCAMS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 102
• Est. completion date: December 1, 2025
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Patients must be > 16 years of age;

2. Patients receiving human leukocyte antigen mismatched and non-cord blood allogeneic hematopoietic stem cell transplantation;

3. Patients who can take oral medication;

4. Patients have to sign an informed consent form before the start of the research procedure.

Exclusion Criteria:

1. Tandem transplantation or multiple transplantations;

2. Patients who are allergic to or cannot tolerate ruxolitinib ;

3. Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements ;

4. Patients who are pregnant or cannot take appropriate contraceptive measures during treatment;

5. Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.

Related Conditions & MeSH terms

• Graft vs Host Disease
• Transplant-Related Disorder

Intervention

Drug:
• Ruxolitinib
Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery. Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (<0.1×10^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery. Model-predicted low risk: regular aGVHD prophylactic regimens.

Locations

Country	Name	City	State
China	Institute of Hematology & Blood Diseases Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severe aGVHD during 100 days after transplantation according to the MAGIC criteria	Incidence of severe aGVHD after transplantation within 100 days. The medical records for each case wil be reviewed by two or three physicians to confirm the aGVHD diagnosis and grading (according to the MAGIC criteria)	100 days after transplantation
Secondary	aGVHD in various target organs during 100 days after transplantation according to the MAGIC criteria	Incidence of aGVHD (any grade) in various target organs. The medical records for each case wil be reviewed by two or three physicians to confirm the aGVHD diagnosis and grading (according to the MAGIC criteria)	100 days after transplantation
Secondary	Overall survival during 1.5 year after transplantation	Patients will be followed up at days 14, 28, 42, 60, 90, 180, 270, 360 and 540 after transplantation; data on survival will be collected.	Days 14, 28, 42, 60, 90, 180, 270, 360 and 540 after transplantation
Secondary	Relapse-free survival rate and relapse rate during 1.5 year after transplantation	Patients will be followed up at days 14, 28, 42, 60, 90, 180, 270, 360 and 540 after transplantation; data on relapse will be collected.	Days 14, 28, 42, 60, 90, 180, 270, 360 and 540 after transplantation
Secondary	Incidence of infections during 1.5 year after transplantation	Infection was defined as meeting one of the following criteria: culture-confirmed presence of bacteria or fungi in a sample collected from a sterile site; polymerase chain reaction-confirmed viremia at = 5000 copies/ml for the cytomegalovirus or = 10000 copies/ml for the Epstein-Barr virus; or body temperature = 38 ? with culture-confirmed presence of pathogens from a non-sterile site.	1.5 year after transplantation
Secondary	Safety of treatment during 100 days after transplantation according to the Common Terminology Criteria for Adverse Events version 5.0	Data on adverse events of treatment will be collected.	100 days after transplantation
Secondary	Total cost of treatment during 1.5 year after transplantation	Data on total cost of treatment will be collected from the medical records.	1.5 year after transplantation